Targets › FAS
1 program from 1 company in 1 trial: 1 Phase 2; Ophthalmology; next expected readout Nov 2028.
Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase CASP8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs CASP8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. (UniProt, P25445)
Open in Phaseline: the race on FAS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| ONL Therapeutics | ONL1204 Ophthalmic Solution Fragment apoptosis stimulator (FAS) receptor inhibitor | FAS | Phase 2 | Geographic Atrophy (GA) | Nov 2028 |
Geographic Atrophy (GA) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.